| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 months ago) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(2 months ago) | |
Mozobil is owned by Genzyme.
Mozobil contains Plerixafor.
Mozobil has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Mozobil are:
- US7897590
- US6987102
Mozobil was authorised for market use on 15 December, 2008.
Mozobil is available in solution;subcutaneous dosage forms.
Mozobil can be used as use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma.
The generics of Mozobil are possible to be released after 22 July, 2023.
Drugs and Companies using PLERIXAFOR ingredient
Market Authorisation Date: 15 December, 2008
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
Dosage: SOLUTION;SUBCUTANEOUS
MOZOBIL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic